Literature DB >> 21424865

The correlation between tumor-infiltrating Foxp3+ regulatory T cells and cyclooxygenase-2 expression and their association with recurrence in resected head and neck cancers.

Dian-Shui Sun1, Miao-Qing Zhao, Ming Xia, Li Li, Yu-Hua Jiang.   

Abstract

The aim of this study was to investigate the correlation between tumor-infiltrating CD4+ CD25(high) Foxp3+ naturally occurring regulatory T cells (Foxp3+ nTregs) and cyclooxygenase-2 (COX-2) expression and their association with local recurrence in resected head and neck cancers. Intratumoral COX-2 and Foxp3+ nTregs expressions were retrospectively assessed using immunohistochemistry. Associations between the clinicopathological characteristics and either intratumoral COX-2 expression or number of Foxp3+ nTregs were tested using the Chi-square test. The correlation between the number of Foxp3+ nTregs and COX-2 expression was tested using Spearman's rank correlation test. Associations between recurrence-free survival (RFS) and either intratumoral COX-2 expression or number of Foxp3+ nTregs were calculated using the Kaplan-Meier method, and factors that may influence the RFS were analyzed by Cox regression. The five-year RFS for all patients was 35.09%. Patient clinicopathological characteristics had no relationship with intratumoral COX-2 expression or the number of Foxp3+ nTregs. However, a positive correlation between intratumoral COX-2 expression and the number of Foxp3+ nTregs was observed (P < 0.001). The RFS of patients with elevated COX-2 expression was significantly worse than that of patients without intratumoral COX-2 expression (P = 0.0228). The RFS of patients with tumors containing >6 Foxp3+ cells was significantly worse than that of patients with tumors containing ≤6 Foxp3+ cells (P = 0.0020). However, by Cox regression analysis, the RFS of all patients was not influenced by intratumoral COX-2 expression (P = 0.100) or the number of Foxp3+ nTregs (P = 0.071). Tumor-infiltrating CD4+ CD25(high) Foxp3+ nTregs were positively correlated with intratumoral COX-2 expression and were associated with a worse RFS in univariate analysis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21424865     DOI: 10.1007/s12032-011-9903-2

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  32 in total

Review 1.  Regulatory T cells and cancer.

Authors:  Helen Y Wang; Rong-Fu Wang
Journal:  Curr Opin Immunol       Date:  2007-02-15       Impact factor: 7.486

2.  Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions.

Authors:  Nobuyoshi Hiraoka; Kaoru Onozato; Tomoo Kosuge; Setsuo Hirohashi
Journal:  Clin Cancer Res       Date:  2006-09-15       Impact factor: 12.531

Review 3.  Regulatory T cells in cancer.

Authors:  Marc Beyer; Joachim L Schultze
Journal:  Blood       Date:  2006-08-01       Impact factor: 22.113

4.  Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.

Authors:  Tyler J Curiel; George Coukos; Linhua Zou; Xavier Alvarez; Pui Cheng; Peter Mottram; Melina Evdemon-Hogan; Jose R Conejo-Garcia; Lin Zhang; Matthew Burow; Yun Zhu; Shuang Wei; Ilona Kryczek; Ben Daniel; Alan Gordon; Leann Myers; Andrew Lackner; Mary L Disis; Keith L Knutson; Lieping Chen; Weiping Zou
Journal:  Nat Med       Date:  2004-08-22       Impact factor: 53.440

Review 5.  Immune restoration in head and neck cancer patients via cyclooxygenase inhibition: an update.

Authors:  S Lang; R Zeidler
Journal:  Int J Immunopathol Pharmacol       Date:  2003 May-Aug       Impact factor: 3.219

6.  COX-2 expression correlates with VEGF-C and lymph node metastases in patients with head and neck squamous cell carcinoma.

Authors:  Panayiotis A Kyzas; Dimitrios Stefanou; Niki J Agnantis
Journal:  Mod Pathol       Date:  2005-01       Impact factor: 7.842

Review 7.  Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy.

Authors:  Stephen Gately; William W Li
Journal:  Semin Oncol       Date:  2004-04       Impact factor: 4.929

8.  The prognostic value of peritumoral regulatory T cells and its correlation with intratumoral cyclooxygenase-2 expression in clear cell renal cell carcinoma.

Authors:  Jin F Li; Yi W Chu; Guo M Wang; Tong Y Zhu; Rui M Rong; Jun Hou; Ming Xu
Journal:  BJU Int       Date:  2008-11-19       Impact factor: 5.588

Review 9.  Human CD4+CD25+ regulatory T cells.

Authors:  Clare Baecher-Allan; Vissia Viglietta; David A Hafler
Journal:  Semin Immunol       Date:  2004-04       Impact factor: 11.130

10.  Increased frequency of regulatory T cells in peripheral blood and tumour infiltrating lymphocytes in colorectal cancer patients.

Authors:  Khoon Lin Ling; Sarah E Pratap; Gaynor J Bates; Baljit Singh; Neil J Mortensen; Bruce D George; Bryan F Warren; Juan Piris; Giovanna Roncador; Stephen B Fox; Alison H Banham; Vincenzo Cerundolo
Journal:  Cancer Immun       Date:  2007-03-28
View more
  14 in total

1.  Prognostic value of CD45 transcriptional expression in head and neck cancer.

Authors:  Mercedes Camacho; Adriana Agüero; Anna Sumarroca; Laura López; Miguel-Ángel Pavón; Francesc-Xavier Avilés-Jurado; Jacinto García; Miquel Quer; Xavier León
Journal:  Eur Arch Otorhinolaryngol       Date:  2017-11-25       Impact factor: 2.503

2.  Tumor infiltrating lymphocytes and survival in patients with head and neck squamous cell carcinoma.

Authors:  Nghia Nguyen; Emily Bellile; Daffyd Thomas; Jonathan McHugh; Laura Rozek; Shama Virani; Lisa Peterson; Thomas E Carey; Heather Walline; Jeffery Moyer; Matthew Spector; Daniel Perim; Mark Prince; Scott McLean; Carol R Bradford; Jeremy M G Taylor; Gregory T Wolf
Journal:  Head Neck       Date:  2016-02-16       Impact factor: 3.147

3.  Pathologic and imunohistochemical characterization of tumoral inflammatory cell infiltrate in invasive penile squamous cell carcinomas: Fox-P3 expression is an independent predictor of recurrence.

Authors:  José Vassallo; André Fellipe Freitas Rodrigues; Antonio Hugo J F M Campos; Rafael Malagoli Rocha; Isabela Werneck da Cunha; Stênio Cássio Zequi; Gustavo Cardoso Guimarães; Francisco Paulo da Fonseca; Ademar Lopes; Antonio Cubilla; Fernando Augusto Soares
Journal:  Tumour Biol       Date:  2015-01-05

Review 4.  TILs in Head and Neck Cancer: Ready for Clinical Implementation and Why (Not)?

Authors:  Astrid De Meulenaere; Tijl Vermassen; Sandrine Aspeslagh; Katrien Vandecasteele; Sylvie Rottey; Liesbeth Ferdinande
Journal:  Head Neck Pathol       Date:  2016-12-28

5.  IL-33 in the tumor microenvironment is associated with the accumulation of FoxP3-positive regulatory T cells in human esophageal carcinomas.

Authors:  Guanglin Cui; Zhenfeng Li; Jingli Ren; Aping Yuan
Journal:  Virchows Arch       Date:  2019-05-06       Impact factor: 4.064

6.  Clinicopathological and prognostic significance of cyclooxygenase-2 expression in head and neck cancer: A meta-analysis.

Authors:  Bin Yang; Lin Jia; Qiaojuan Guo; Hui Ren; Yanping Hu; Tao Xie
Journal:  Oncotarget       Date:  2016-07-26

Review 7.  HYPE or HOPE: the prognostic value of infiltrating immune cells in cancer.

Authors:  Tristan A Barnes; Eitan Amir
Journal:  Br J Cancer       Date:  2017-07-13       Impact factor: 7.640

Review 8.  IRX-2 natural cytokine biologic for immunotherapy in patients with head and neck cancers.

Authors:  Gregory T Wolf; Jeffrey S Moyer; Michael J Kaplan; Jason G Newman; James E Egan; Neil L Berinstein; Theresa L Whiteside
Journal:  Onco Targets Ther       Date:  2018-06-28       Impact factor: 4.147

9.  The tumor microenvironment contribution to development, growth, invasion and metastasis of head and neck squamous cell carcinomas.

Authors:  Sittichai Koontongkaew
Journal:  J Cancer       Date:  2013-01-01       Impact factor: 4.207

Review 10.  Immune Landscape in Tumor Microenvironment: Implications for Biomarker Development and Immunotherapy.

Authors:  Karim Pérez-Romero; Ramón M Rodríguez; Amedeo Amedei; Gwendolyn Barceló-Coblijn; Daniel H Lopez
Journal:  Int J Mol Sci       Date:  2020-08-01       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.